Celcuity Inc.

Rentabilité sur six mois: -3.81%
Rendement en dividendes: 0%
Secteur: Healthcare

12.11 $

0 $ 0%
8.21 $
19.15 $

paper.min_max_per_year

Calendrier des promotions Celcuity Inc.

À propos de l'entreprise Celcuity Inc.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Paramètres de base

IPO date
2017-09-20
ISIN
US15102K1007
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт

Grade

Sous-estimation
Nom Signification Grade
P/S 0 0
P/BV 4.48 4
P/E 0 0
Efficacité
Nom Signification Grade
ROA -51.23 0
ROE -87.54 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.8648 10
Debt/Ratio 0.3996 10
Debt/Equity 1.12 8
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 1092.28 10
Rentabilité EPS, % 220.1 10

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 12.11 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 12.92 $ 0 $ 0 $ -6.27 % 0 % 0 %
common.calendar.number_days.30d 10.44 $ 12.11 $ 13.05 $ 16 % 0 % 0 %
common.calendar.number_days.90d 9.23 $ 8.21 $ 13.05 $ 31.2 % 0 % 0 %
common.calendar.number_days.180d 12.59 $ 8.21 $ 13.16 $ -3.81 % 0 % 0 %
common.calendar.number_days.1y 16.59 $ 8.21 $ 19.15 $ -27 % 0 % 0 %
common.calendar.number_days.3y 10.04 $ 7.55 $ 21.6 $ 20.62 % 0 % 0 %
common.calendar.number_days.5y 5.28 $ 5.1 $ 30.93 $ 129.36 % 0 % 0 %
common.calendar.number_days.10y 4.42 $ 4.42 $ 30.93 $ 273.98 % 0 % 0 %
common.calendar.number_days.ytd 11.95 $ 8.21 $ 13.62 $ 1.34 % 0 % 0 %

Principaux propriétaires

Contenu dans l'ETF

ETF
Partager, %
Rentabilité pour l'année, %
Commission, %
Jacob Forward ETF 0.85997 26.5 0.75
iShares Morningstar Small-Cap Growth ETF 0.00891 601.87 0.06
iShares Morningstar Small-Cap ETF 0.00435 328.78 0.25
0,29319,050,35

Entreprises similaires



Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Brian F. Sullivan Co-Founder, Chairman & CEO 478.12k 1962 (63 année)
Dr. Lance G. Laing Ph.D. Co-Founder, Chief Science Officer, VP, Secretary & Director 389.55k 1962 (63 année)
Ms. Vicky Hahne Chief Financial Officer 281.59k 1966 (59 années)
Dr. John R. MacDonald Dabt, Ph., Ph.D. Senior Vice President of R&D N/A 1955 (70 années)
Ms. Sheri Smith Acting Head of Clinical Operations N/A
Mr. Igor Gorbatchevsky M.D. Chief Medical Officer N/A
Mr. Eldon C. Mayer III, M.B.A. Chief Commercial Officer N/A 1961 (64 année)
Dr. Charlotte Moser M.B.A., M.D., M.Sc., Ph.D. Senior Vice President of Clinical Development

Informations sur l'entreprise

Adresse: United States, Minneapolis. MN, 16305–36th Avenue North - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.celcuity.com